Wu X, Yang Y. Research progress on drug delivery systems for curcumin in the treatment of gastrointestinal tumors. World J Gastrointest Oncol 2023; 15(8): 1342-1348 [PMID: 37663948 DOI: 10.4251/wjgo.v15.i8.1342]
Corresponding Author of This Article
Yang Yang, MM, Associate Professor, Department of Respiratory Oncology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150081, Heilongjiang Province, China. 78100178@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1342-1348 Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1342
Research progress on drug delivery systems for curcumin in the treatment of gastrointestinal tumors
Xin Wu, Yang Yang
Xin Wu, Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China
Yang Yang, Department of Respiratory Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China
Author contributions: Wu X and Yang Y contributed equally to the conception, design, and literature search; Wu X drafted the manuscript and prepared the table and figure; Yang Y modified and revised the manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yang Yang, MM, Associate Professor, Department of Respiratory Oncology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150081, Heilongjiang Province, China. 78100178@qq.com
Received: May 11, 2023 Peer-review started: May 11, 2023 First decision: May 31, 2023 Revised: June 11, 2023 Accepted: July 11, 2023 Article in press: July 11, 2023 Published online: August 15, 2023 Processing time: 91 Days and 13.2 Hours
Abstract
Curcumin is a natural compound with a diketone structure, which can control the growth, metastasis, recurrence, neovascularization, invasion, and drug resistance of gastrointestinal tumors by inhibiting nuclear factor κB, overexpression of tumor cells, vascular endothelial growth factor, etc. However, due to the low bioavailability of curcumin formulation, it did not fully exert its pharmacological effects, and its application and development in the treatment of various malignant tumors are still limited. This review summarizes the research on drug delivery systems of curcumin combating digestive tract tumors in order to further reduce the toxic side effects of curcumin-containing drugs and fully exert their pharmacological activities, and improve their bioavailability and clinical value.
Core Tip: Curcumin can control the growth, metastasis, recurrence, neovascularization, invasion, and drug resistance of gastrointestinal tumors by inhibiting nuclear factor κB, overexpression of tumor cells, and vascular endothelial growth factor. It is important to clarify the application value of curcumin by different drug delivery systems to optimize the treatment of gastrointestinal tumors.
